| Identification | Back Directory | [Name]
Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans- | [CAS]
2366152-15-8 | [Synonyms]
Cyclobutanecarboxylic acid, 3-[(3R)-3-[1-[5-chloro-4-[[(1R)-1-(2,4-dichlorophenyl)ethyl]amino]-6-methyl-2-pyrimidinyl]-3-azetidinyl]-1-piperidinyl]-1-methyl-, trans- | [Molecular Formula]
C27H34Cl3N5O2 | [MOL File]
2366152-15-8.mol | [Molecular Weight]
566.95 |
| Chemical Properties | Back Directory | [Boiling point ]
706.9±70.0 °C(Predicted) | [density ]
1.387±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
4.09±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Zelnecirnon, also known as RPT193, is a CCR4 antagonist that blocks the recruitment of Th2 cells in order to treat inflammatory diseases (taken orally). The Phase 1b trial, which was conducted in patients with atopic dermatitis, found that markable improvement occurred after 4 weeks with little side effects. A Phase 2 clinical trial is currently being conducted to evaluate the efficacy and safety of Zelnecirnon, with an expected end date of September 2023. | [storage]
Store at -20°C |
|
|